Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555751 | 0.80 | KMT2A (0.54) | KMT2AL3MBTL1KDM1AMAOBKCNA3 | |
| SCHEMBL7374289 | 0.79 | L3MBTL1 (0.74) | KMT2AL3MBTL1KDM1AMAOBKCNA3 | |
| SCHEMBL1851171 | 0.79 | KMT2A (0.91) | KMT2AL3MBTL1USP2 | |
| SCHEMBL24976021 | 0.77 | L3MBTL1 (0.53) | KMT2AL3MBTL1KDM1ASLC6A4 | |
| SCHEMBL24977220 | 0.77 | L3MBTL1 (0.53) | KMT2AL3MBTL1KDM1ASLC6A4 | |
| SCHEMBL24975769 | 0.77 | L3MBTL1 (0.53) | KMT2AL3MBTL1KDM1ASLC6A4 | |
| SCHEMBL29410965 | 0.77 | L3MBTL1 (1.00) | KMT2AL3MBTL1USP2 | |
| SCHEMBL20967988 | 0.77 | L3MBTL1 (1.00) | KMT2AL3MBTL1USP2 | |
| SCHEMBL4794886 | 0.77 | L3MBTL1 (1.00) | KMT2AL3MBTL1USP2 | |
| SCHEMBL28249801 | 0.77 | KMT2A (0.56) | KMT2AL3MBTL1KDM1AMAOBKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680335-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4680336-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024196788-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024196786-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | KMT2A 4683/4885L3MBTL1 1942/4885KDM1A 4062/4885 |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | KMT2A 4575/4885L3MBTL1 1893/4885KDM1A 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.